Cancer NetworkOriginal article
<![CDATA[Enfortumab Vedotin Combo Shows Real-World Benefit in Urothelial Carcinoma]]>
Data Readoutpositiveenfortumab vedotinpembrolizumabPositive
AI Analysis
Summary
Enfortumab vedotin combined with pembrolizumab demonstrated a 50.2% objective response rate in a real-world setting for patients with metastatic/locally advanced urothelial carcinoma. This real-world evidence supports the clinical benefit of the combination therapy.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
50.2% ORR (objective response rate) in real-world setting
Importance:5/10
Sentiment:
0.70
urothelial carcinomareal-world datacombination therapyoncology
Read the original article
Published by Cancer Network on August 25, 2026 5:00 PM